. Author manuscript; available in PMC: 2013 Oct 28.

Published in final edited form as: Bayesian Anal. 2012 Sep;7(3):10.1214/12-BA720. doi: 10.1214/12-BA720

Table 2.

Simulation study of the CRM dose-finding trial with heterogeneous subgroups assuming the prior with level 2 prior parameters $σ_{α, φ}^{2} = σ_{β, φ}^{2} = 25$ and U_φ = 2. The percentage of times that the method selected each dose level as the final MTD in each subgroup (%recommendation) and the numbers of patients who were treated at each dose level (No. of patients) out of 36 patients are summarized. Correct selections are marked in bold-face.

Subgroup	Dose level	d₁	d₂	d₃	d₄	d₅	d₆
1	True prob. tox	.05	.10	.15	.30	.50	.65
	%recommendation	.05	.16	.30	.36	.07	.04
	No. of patients	2.1	3.1	4.5	3.6	1.1	.4
2	True prob. tox	.10	.20	.30	.45	.60	.70
	%recommendation	.08	.26	.39	.24	.02	.01
	No. of patients	1.8	2.9	3.3	2.0	.6	.1
3	True prob. tox	.15	.30	.45	.55	.65	.75
	%recommendation	.12	.34	.32	.16	.02	.01
	No. of patients	1.2	2.2	1.9	1.0	.3	.1
4	True prob. tox	.10	.10	.10	.20	.20	.20
	%recommendation	.05	.20	.32	.31	.09	.02
	No. of patients	.5	.9	1.0	.8	.2	.1